↓ Skip to main content

PROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer Vaccine

Overview of attention for article published in Clinical Cancer Research, June 2011
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (98th percentile)
  • High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news
5 news outlets
blogs
1 blog
policy
2 policy sources
twitter
1 tweeter
patent
8 patents
wikipedia
1 Wikipedia page

Citations

dimensions_citation
436 Dimensions

Readers on

mendeley
459 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
PROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer Vaccine
Published in
Clinical Cancer Research, June 2011
DOI 10.1158/1078-0432.ccr-10-3126
Pubmed ID
Authors

Martin A. Cheever, Celestia S. Higano

Abstract

Sipuleucel-T (PROVENGE; Dendreon) is the first therapeutic cancer vaccine to be approved by the U.S. Food and Drug Administration. In men who have metastatic castration-resistant prostate cancer with no or minimal symptoms, sipuleucel-T prolongs median survival by 4.1 months compared with results in those treated with placebo. At 3 years, the proportion of patients in the vaccine group who were alive was 50% higher than that in the control group (31.7% versus 21.7%, respectively). Sipuleucel-T, which is designed to elicit an immune response to prostatic acid phosphatase, uses the patient's own immune system to recognize and combat his cancer. Currently, no other agents are available that offer a survival benefit for this population of asymptomatic patients who have not been treated with chemotherapy, except for docetaxel (whose inherent toxicities often lead patients and physicians to delay administration until symptoms develop). Straightforward strategies to increase the efficacy of sipuleucel-T are likely to provide even greater benefit. The preclinical and clinical development of sipuleucel-T is reviewed, and approaches to enhance efficacy are considered herein.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 459 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 2 <1%
United States 2 <1%
Chile 1 <1%
China 1 <1%
Unknown 453 99%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 99 22%
Student > Bachelor 78 17%
Student > Master 69 15%
Researcher 56 12%
Other 24 5%
Other 56 12%
Unknown 77 17%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 72 16%
Agricultural and Biological Sciences 72 16%
Medicine and Dentistry 71 15%
Immunology and Microbiology 47 10%
Pharmacology, Toxicology and Pharmaceutical Science 37 8%
Other 68 15%
Unknown 92 20%

Attention Score in Context

This research output has an Altmetric Attention Score of 56. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 June 2022.
All research outputs
#599,756
of 21,702,786 outputs
Outputs from Clinical Cancer Research
#396
of 12,309 outputs
Outputs of similar age
#5,450
of 293,810 outputs
Outputs of similar age from Clinical Cancer Research
#2
of 146 outputs
Altmetric has tracked 21,702,786 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 12,309 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.2. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 293,810 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 146 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.